2015

Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages

L Tracey
A Regan
D Mak
The University of Notre Dame Australia, donna.mak@nd.edu.au
P Effler

Follow this and additional works at: http://researchonline.nd.edu.au/med_article

Part of the Medicine and Health Sciences Commons

This article was originally published as:
Tracey, L., Regan, A., Mak, D., & Effler, P. (2015). Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages. Infection Control and Hospital Epidemiology, 36 (5), 608-610.

Original article available here:
https://doi.org/10.1017/ice.2015.16

This article is posted on ResearchOnline@ND at
http://researchonline.nd.edu.au/med_article/817. For more information, please contact researchonline@nd.edu.au.
Tracey, L., Regan, A., Mak, D., and Effler, P. (2015) Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages. *Infection Control and Hospital Epidemiology, 36*(5), 608-610.
doi: [10.1017/ice.2015.16](https://doi.org/10.1017/ice.2015.16)
Studies have demonstrated that healthcare personnel (HCP) have concerns about the potential side effects of trivalent inactivate influenza vaccine (IIV3).1-3 A recent meta-analysis of reasons HCP refuse IIV3 indicates the strongest predictors of vaccine acceptance are belief that the vaccine is safe and belief the vaccine does not cause the disease it is meant to prevent.1
Adverse events following influenza immunisation reported by healthcare personnel using SMS-based active surveillance

Tracey L, MPH\textsuperscript{a} Regan AK, MPH\textsuperscript{a,b} Mak, DB, MPH\textsuperscript{a,c} Effler PV, MD\textsuperscript{a,b}

\textsuperscript{a}Communicable Disease Control Directorate, Western Australian Department of Health, Perth, Western Australia, Australia

\textsuperscript{b}School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia

\textsuperscript{c}School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia

SHORT TITLE: Adverse events following immunisation in HCP

Contact details: Lauren Tracey, Epidemiologist, Communicable Disease Control Directorate, Western Australian Department of Health; Mailing: 227 Stubbs Terrace, Shenton Park, Western Australia, 6008, Australia; Phone: +61 89388 4876, Email: Lauren.Tracey@health.wa.gov.au

Word count: 903
Introduction

Studies have demonstrated that healthcare personnel (HCP) have concerns about the potential side effects of trivalent inactivate influenza vaccine (IIV3).\textsuperscript{1-3} A recent meta-analysis of reasons HCP refuse IIV3 indicates the strongest predictors of vaccine acceptance are belief that the vaccine is safe and belief the vaccine does not cause the disease it is meant to prevent.\textsuperscript{1}

Timely vaccine safety information for each new seasonal IIV3 vaccine can be used to reassure HCP. In addition, the ability to provide real-time safety profiling of new vaccines should form part of emergency preparedness planning, for example in the case of rapid development and rollout of vaccines in a pandemic.

Despite ready access to vaccines and concerted efforts to promote uptake, influenza vaccination coverage among HCP in Australia has historically been low, ranging from 18-66%.\textsuperscript{5} In a review of 32 studies from the United States (13), Canada (5), Europe (11) and others (3), Hofmann et al. found influenza vaccine coverage of less than 50% in HCP in the majority (26/32, 81%) of these studies.\textsuperscript{6}

In 2014, the Western Australian Department of Health (“WA Health”) developed the Follow-up and Active Surveillance of Trivalent Influenza Vaccine in HCP (FASTHealth) program. FASTHealth is an SMS-based, active influenza vaccine safety monitoring program intended to be implemented at the start of each season’s annual HCP vaccination program.
Methods

WA Health provides free IIV3 for staff working in government health facilities and maintains a centralised record keeping system for recording HCP influenza immunisation. In 2014, HCP were asked at the time of vaccination to participate in the FASTHealth program to monitor adverse events following immunisation (AEFIs). HCP who consented and provided a mobile phone number were sent a text message (or ‘SMS’) seven days after vaccination querying whether they had experienced any ‘reaction, fever or illness’ following vaccination.

A second SMS was sent 24 hours later to anyone who did not reply to the first message. HCP who responded “Yes” to either message were sent a link to a mobile phone survey to record the details of their AEFI. Those who opted not to complete the smart phone survey and those who did not reply to either SMS were telephoned to ascertain specifics of any AEFI via a standardised interview with a research nurse. Both surveys were identical in content and asked whether the participant experienced fever, headache, fatigue, vomiting, rash, rigors, convulsions or swelling or pain at the injection site. Other reported potential side-effects were recorded verbatim/as written.

Results

Between 19 March and 20 May 2014, 1,624 HCP, including medical, administration and support staff, were sent an SMS soliciting whether they experienced an AEFI. The majority were female (81%) and between 18-44 years of age (56%); 835 HCP received intradermal IIV3 (Intanza®: 51.4%) and 789 received an intramuscular IIV3 (Vaxigrip®: 48.3%; Fluvax®: 0.3%).
Of those who were sent an SMS message, 1,432 (88%) replied. A total of 239 (17%) of the respondents replied affirmatively that they had experienced one or more reactions to the vaccine. Of those reporting reactions, 184 (77%) provided details regarding the AEFI: 66 via the mobile phone survey and 118 by telephone. The remaining 55 HCP were lost to follow-up.

Among the 192 HCP who did not reply to the SMS, 65 (34%) were subsequently reached by telephone and 20 (31%) of these reported an event. In aggregate, 1,442 HCP provided complete information regarding the occurrence of AEFI, of which 204 (14.1% [95% CI 12.2-16.1%]) reported at least one reaction (Figure).

**Figure. Responses to the FASTHealth program 19 March – 20 May 2014.**

No severe adverse events were reported. A total of 137 HCP reported at least one systemic symptom, most commonly fatigue (3.8% [95% CI 2.8-4.8%]), headache (3.7% [95% CI 2.7-4.7%]) or respiratory symptoms (3.7% [95% CI 2.7-4.7%]). 115 HCP reported redness, pain or swelling at the injection site (8.0% [95% CI 6.5-1.7%]). These results were in keeping with the documented safety profile of IIV3 vaccine.

**Discussion**

Use of SMS technology in the FASTHealth program allowed rapid, active surveillance of the safety of IIV3 offered free to HCP as part of the annual influenza program. Consistent with previous vaccine safety investigations of seasonal IIV3 in HCP, the proportion reporting a potential side-effect was low.4,7
As the antigenic components of the influenza vaccine can change season-to-season and safety profiles from previous seasons’ formulations may not be applicable to current vaccines, it is particularly important to monitor the safety of IIV3 each year. Our findings demonstrate the feasibility of implementing a timely, resource-conserving, vaccine safety monitoring system among HCP each year during influenza vaccination season.

Previous methods to capture AEFI following IIV3 in HCP mainly include self-report paper questionnaires, which require significantly more time to capture, record and analyse the data. Smartphone penetration in Australia was reported at 65% in 2013, making it a suitable market for the use of such technology. In the same survey, smartphone use is reportedly less common in other countries such as the United Kingdom (62%) and the United States (56%), however overall there is increasing smartphone penetration globally, and in future the use of this technology has applications any time a new vaccine is introduced.

The information obtained can be used to reassure HCP regarding the reactogenicity of the vaccine, and potentially used to improve uptake among HCP. Future studies should investigate communication strategies for informing HCP about the safety of IIV3. Considering the potential to prevent disease in HCP, their families and their patients, opportunities to disseminate safety data to HCP in real time should be further explored.
Acknowledgements

Financial Support:

The FASTHealth program is funded by the Department of Health, Western Australia

Potential Conflicts of Interest:

All Authors report no conflicts of interest relevant to this letter

Thank-yous:

The Authors would like to acknowledge the work of the Research Nurses at the Vaccine Trials Group, Telethon Kids Institute, for their work in telephone follow up of the adverse events, and Sharon Gough for her assistance in data management of the program.
References


Data sets and country reports. 2013. Accessed 01 January 2015. Available from: 
1,624 health care professionals (HCPs) sent a SMS

1,432 (88%) HCPs replied to the message

239 (17%) HCPs replied "Yes" indicating they had experienced an adverse event following immunisation (AEFI)

184 (77%) HCPs who experienced an AEFI provided details
- 66 via mobile phone survey
- 118 via telephone survey

1,193 (83%) HCPs replied "No" indicating they experience no AEFI

192 (12%) HCPs did not reply to the message and were lost to follow-up

55 (23%) lost to follow-up